AIM ImmunoTech Extends Ampligen Patent Protection to 2039 with Key Cancer Combination Therapy
Event summary
- AIM ImmunoTech secured a U.S. patent covering Ampligen (rintatolimod) in combination with pembrolizumab (Keytruda) for cancer treatment, expiring December 20, 2039.
- The patent includes broad claims for combination therapy across multiple cancer types, including pancreatic, skin, and colorectal cancers.
- AIM holds additional patents in the U.S., Netherlands, and Japan covering Ampligen with PD-1 and PD-L1 checkpoint inhibitors.
- The patent strengthens AIM's IP estate for Ampligen's role in cancer immunotherapy, particularly in pancreatic cancer.
The big picture
AIM ImmunoTech's new patent extends its intellectual property protection for Ampligen, reinforcing its strategic focus on cancer immunotherapy. The patent covers a combination therapy with pembrolizumab, a leading PD-1 checkpoint inhibitor, which aligns with broader industry trends toward combination treatments in oncology. This move strengthens AIM's long-term competitive positioning in the oncology space, particularly in pancreatic cancer, where treatment options remain limited.
What we're watching
- IP Strategy
- How AIM will leverage this patent to strengthen its market position in oncology combination therapies.
- Clinical Progress
- The pace at which AIM advances Ampligen through late-stage trials, particularly in pancreatic cancer.
- Regulatory Dynamics
- Whether AIM can secure similar patent protections in other key markets beyond the U.S.